🇺🇸 FDA
Patent

US 8372835

Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases

granted A61PA61P1/16A61P11/06

Quick answer

US patent 8372835 (Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases) held by Vertex Pharmaceuticals Incorporated expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Feb 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
2
CPC classes
A61P, A61P1/16, A61P11/06, A61P15/10, A61P19/00